Tailoring therapy for heart failure: The pharmacogenomics of adrenergic receptor signaling

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue , 2014, Pages 267-273

  Femminella, Grazia Daniela ^a   Barrese, Vincenzo ^a,b   Ferrara, Nicola ^a,c   Rengo, Giuseppe ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c IRCCS   (Italy)

Author keywords

Adrenergic system; Functional recovery; Polymorphisms; Blockers

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CYTOCHROME P450 2D6; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 5; PLACEBO;

ALPHA 2AR GENE; ALPHA 2CAR GENE; BETA 1AR GENE; CARDIOVASCULAR MORTALITY; CYP2D6 GENE; GENETIC VARIABILITY; GRK2 GENE; GRK5 GENE; HEART FAILURE; HUMAN; NONHUMAN; PHARMACOGENOMICS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84922700127     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S49799     Document Type: Review

References (56)

1. Rengo F, Leosco D, Iacovoni A, et al. [Epidemiology and risk factors for heart failure in the elderly]. Ital Heart J. 2004;5(Suppl 10):9S–16S. Italian.
2. Yancy CW, Jessup M, Bozkurt B, et al; Writing Committee Members; American College of Cardiology Foundation/American Heart Association Task force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–e327.
3. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the inci­dence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168(19):2138–2145.
4. Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol Med. 2007;13(12): 503–511.
5. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113(6): 739–753.
6. Azuma J, Nonen S. Chronic heart failure: beta-blockers and pharmacogenetics. Eur J Clin Pharmacol. 2009;65(1):3–17.
7. CIBIS II Investigators and Committees. The Cardiac Insuffi­ciency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.
8. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Conges­tive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2009.
9. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658.
10. Fleg JL, Piña IL, Balady GJ, et al. Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000;102(13): 1591–1597.
11. Shin J, Johnson JA. Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev. 2010;15(3):187–196.
12. Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future direc­tions. Clin Pharmacol Ther. 2011;89(3):366–378.
13. Rengo G, Lymperopoulos A, Koch WJ. Future g protein-coupled recep­tor targets for treatment of heart failure. Curr Treat Options Cardiovasc Med. 2009;11(4):328–338.
14. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol. 2011;50(5): 785–792.
15. Leosco D, Rengo G, Iaccarino G, et al. Exercise training and beta-blocker treatment ameliorate age-dependent impairment of beta-adrenergic receptor signaling and enhance cardiac responsiveness to adrenergic stimulation. Am J Physiol Heart Circ Physiol. 2007;293(3): H1596–H1603.
16. Ciccarelli M, Chuprun JK, Rengo G, et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation. 2011;123(18): 1953–1962.
17. Rengo G, Perrone-Filardi P, Femminella GD, et al. Targeting the β-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ Heart Fail. 2012;5(3):385–391.
18. Lymperopoulos A, Rengo G, Koch WJ. GRK2 inhibition in heart failure: something old, something new. Curr Pharm Des. 2012;18(2): 186–191.
19. Petrofski JA, Koch WJ. The beta-adrenergic receptor kinase in heart failure. J Mol Cell Cardiol. 2003;35:1167–1174.
20. Rengo G, Zincarelli C, Femminella GD, et al. Myocardial β(2) -adrenoceptor gene delivery promotes coordinated cardiac adap­tive remodelling and angiogenesis in heart failure. Br J Pharmacol. 2012;166(8):2348–2361.
21. Barrese V, Taglialatela M. New advances in beta-blocker therapy in heart failure. Front Physiol. 2013;4:323.
22. Rengo G, Galasso G, Femminella GD, et al. Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. Eur J Prev Cardiol. 2014;21(1):4–11.
23. Rengo G, Leosco D, Zincarelli C, et al. Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am J Physiol Heart Circ Physiol. 2010;298(6): H2032–H2038.
24. Raake PW, Vinge LE, Gao E, et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res. 2008;103(4):413–422.
25. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol. 2011;57(3):356–365.
26. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci U S A. 2009;106(14):5825–5830.
27. Lymperopoulos A, Rengo G, Zincarelli C, Soltys S, Koch WJ. Modulation of adrenal catecholamine secretion by in vivo gene trans­fer and manipulation of G protein-coupled receptor kinase-2 activity. Mol Ther. 2008;16(2):302–307.
28. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med. 2007;13(3):315–323.
29. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW, Koch WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem. 2010;285(21): 16378–16386.
30. Rengo G, Lymperopoulos A, Zincarelli C, et al. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation. 2009;119(1):89–98.
31. Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95(12): 7000–7005.
32. Rengo G, Lymperopoulos A, Zincarelli C, et al. Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2)-adrenoceptor-catecholamine production axis in heart failure. Br J Pharmacol. 2012;166(8):2430–2440.
33. Rengo G, Cannavo A, Liccardo D, et al. Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis and remodeling in heart failure. Circ Heart Fail. 2013;6(6):1259–1267.
34. von Homeyer P, Schwinn DA. Pharmacogenomics of β-adrenergic receptor physiology and response to beta-blockade. Anesth Analg. 2011;113(6):1305–1318.
35. Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol. 2002;39(2):155–160.
36. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem. 2002;277(34):30429–30435.
37. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274(18):12670–12674.
38. Rathz DA, Gregory KN, Fang Y, Brown KM, Liggett SB. Hierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signaling. J Biol Chem. 2003;278(12): 10784–10789.
39. Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9(10):1300–1305.
40. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103(30):11288–11293.
41. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000;275(30):23059–23064.
42. Talameh JA, Lanfear DE. Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep. 2012;9(1):23–32.
43. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol. 2003;43:381–411.
44. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994;33(32):9414–9419.
45. Panebra A, Wang WC, Malone MM, et al. Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes. PloS One. 2010;5(7):e11819.
46. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008;14(5):510–517.
47. Lobmeyer MT, Wang L, Zineh I, et al. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011;21(1):42–49.
48. Chan SW, Hu M, Tomlinson B. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure. Expert Opin Drug Metab Toxicol. 2012;8(7):767–790.
49. Terra SG, Hamilton KK, Pauly DF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics. 2005;15(4):227–234.
50. de Groote P, Helbecque N, Lamblin N, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics. 2005;15(3):137–142.
51. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–1667.
52. Kurnik D, Li C, Sofowora GG, et al. Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogene Genomics. 2008;18(10):895–902.
53. Fiuzat M, Neely ML, Starr AZ, et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail. 2013;15(3):258–266.
54. Baudhuin LM, Miller WL, Train L, et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol. 2010;106(3):402–408.
55. Shin J, Lobmeyer MT, Gong Y, et al. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol. 2007;99(2):250–255.
56. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiv­ing beta-blocker therapy after an acute coronary syndrome. JAMA. 2005;294(12):1526–1533.